Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) shot up 2.1% during trading on Thursday . The stock traded as high as $7.40 and last traded at $7.40. 7,100 shares were traded during mid-day trading, a decline of 50% from the average session volume of 14,343 shares. The stock had previously closed at $7.25.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Idorsia in a report on Monday, June 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.
Read Our Latest Analysis on IDRSF
Idorsia Stock Performance
Idorsia Company Profile
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Further Reading
- Five stocks we like better than Idorsia
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
- MarketBeat Week in Review – 06/29 – 07/03
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
